Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Afinitor

Afinitor 2.5 mg tablets Afinitor 5 mg tablets Afinitor 10 mg tablets · Abschnitt 4.5 · PDF-Seite 9–10

HOS-210324 · Präparat HOS-154501

9  Potent and moderate CYP3A4 inducers Rifampicin AUC ↓63% Avoid the use of concomitant (range 0-80%) potent CYP3A4 inducers. If Cmax ↓58% patients require co-administration (range 10-70%) of a potent CYP3A4 inducer, an Dexamethasone Not studied. Decreased exposure Afinitor dose increase from 10 mg expected. daily up to 20 mg daily should be Carbamazepine, Not studied. Decreased exposure considered using 5 mg increments phenobarbital, phenytoin expected. or less applied on Day 4 and 8 Efavirenz, nevirapine Not studied. Decreased exposure following start of the inducer. This expected. dose of Afinitor is predicted to adjust the AUC to the range observed without inducers. However, there are no clinical data with this dose adjustment. If treatment with the inducer is discontinued, consider a washout period of at least 3 to 5 days (reasonable time for significant enzyme de-induction), before the Afinitor dose is returned to the dose used prior to initiation of the co-administration. St John’s Wort (Hypericum Not studied. Large decrease in Preparations containing St John’s perforatum) exposure expected. Wort should not be used during treatment with everolimus

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) dexamethasone (HOS-084535) efavirenz (HOS-087947) nevirapine (HOS-088064) phenytoin (HOS-084531)